Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S177-S187

  Zádori, Dénes ^a   Veres, Gábor ^a   Szalárdy, Levente ^a   Klivényi, Péter ^a   Toldi, József ^b,c   Vécsei, László ^a,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Alzheimer's disease; glutamate excitotoxicity; kynurenic acid amides; memantine; neurodegeneration; neuroprotection; therapy

Indexed keywords

AMYLOID BETA PROTEIN; GLYCINE; IFENPRODIL; ION CHANNEL; KYNURENIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYAMINE; TAU PROTEIN; AMINO ACID RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; NR2B NMDA RECEPTOR;

ALZHEIMER DISEASE; CONFERENCE PAPER; ELECTRIC POTENTIAL; EXCITOTOXICITY; HUMAN; NEUROANATOMY; NEUROTRANSMISSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84920607191     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132621     Document Type: Conference Paper

References (123)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Zadori D, Datki Z, PenkeB(2007) [The role of chronic brain hypoperfusion in the pathogenesis of Alzheimer's disease-facts and hypotheses]. Ideggyogy Sz 60, 428-437.
3. Scott KR, Barrett AM (2007) Dementia syndromes: Evaluation and treatment. Expert Rev Neurother 7, 407-422.
4. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
5. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
6. Vogels OJ, Broere CA, ter Laak HJ, ten Donkelaar HJ, Nieuwenhuys R, Schulte BP (1990) Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol Aging 11, 3-13.
7. Neill D (1995) Alzheimer's disease: Maladaptive synaptoplasticity hypothesis. Neurodegeneration 4, 217-232.
8. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW,Davis DG, Markesbery WR (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18, S99-105.
9. Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA (2005) Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol 18, 218-223.
10. Perl DP, Purohit DP (1997) Proposal to revise the morphologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18, S81-S84.
11. Van Hoesen G, Pandya DN (1975) Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. I. Temporal lobe afferents. Brain Res 95, 1-24.
12. Van Hoesen G, Pandya DN, Butters N (1975) Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. II. Frontal lobe afferents. Brain Res 95, 25-38.
13. Van Hoesen GW, Pandya DN (1975) Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey. III. Efferent connections. Brain Res 95, 39-59.
14. Gomez-IslaT, Price JL,McKeelDWJr,Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500.
15. Price JL,Ko AI,Wade MJ, Tsou SK,McKeelDW,Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58, 1395-1402.
16. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
17. Hooper WM, Vogel FS (1976) The limbic system in Alzheimer's disease. Am J Pathol 85, 1-19.
18. Augustinack JC, Helmer K, Huber KE, Kakunoori S, Zollei L, Fischl B (2010) Direct visualization of the perforant pathway in the human brain with ex vivo diffusion tensor imaging. Front Hum Neurosci 4, 42.
19. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 1372-1384.
20. Witter MP, Wouterlood FG, Naber PA, Van Haeften T (2000) Anatomical organization of the parahippocampalhippocampal network. Ann N Y Acad Sci 911, 1-24.
21. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508.
22. Braak H, Braak E, Yilmazer D, Bohl J (1996) Functional anatomy of human hippocampal formation and related structures. J Child Neurol 11, 265-275.
23. Shah A, Jhawar SS, Goel A (2012) Analysis of the anatomy of the Papez circuit and adjoining limbic system by fiber dissection techniques. J Clin Neurosci 19, 289-298.
24. Kohler C (1985) Intrinsic projections of the retrohippocampal region in the rat brain. I. The subicular complex. J Comp Neurol 236, 504-522.
25. Sah P, Faber ES, Lopez De Armentia M, Power J (2003) The amygdaloid complex: Anatomy and physiology. Physiol Rev 83, 803-834.
26. McDonald AJ (1998) Cortical pathways to the mammalian amygdala. Prog Neurobiol 55, 257-332.
27. Milner B, Squire LR, Kandel ER (1998) Cognitive neuroscience and the study of memory. Neuron 20, 445-468.
28. Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42, 1097-1105.
29. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
30. Kirvell SL, Esiri M, Francis PT (2006) Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98, 939-950.
31. Kashani A, Lepicard E, Poirel O,Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S (2008) Loss of VGLUT1 and VGLUT2in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 29, 1619-1630.
32. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC (2013) Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging 34, 2341-2351.
33. Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, Bellanti F, Laconca L, Romano AD, Padalino I, LaFerla FM, Nicoletti F, Cuomo V, Vendemiale G (2012) Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging 33, 1121 e1121-1112.
34. Canas PM, Simoes AP, Rodrigues RJ, Cunha RA (2014) Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer's disease. Neuropharmacology 76(Pt A), 51-56.
35. Jellinger KA (2012) Neuropathological subtypes of Alzheimer's disease. Acta Neuropathol 123, 153-154.
36. Mota SI, Ferreira IL, Rego AC (2014) Dysfunctional synapse in Alzheimer's disease-A focus on NMDA receptors. Neuropharmacology 76(Pt A), 16-26.
37. Rank KB, Pauley AM, Bhattacharya K,Wang Z, Evans DB, Fleck TJ, Johnston JA, Sharma SK (2002) Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett 514, 263-268.
38. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL (2013) The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev 12, 757-763.
39. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O (2011) Endogenous amyloidbeta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69, 819-830.
40. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I (2009) Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12, 1567-1576.
41. Sokolow S, Luu SH, Nandy K, Miller CA, Vinters HV, Poon WW, Gylys KH (2012) Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiol Dis 45, 381-387.
42. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807.
43. Yu W, Lu B (2012) Synapses and dendritic spines as pathogenic targets in Alzheimer's disease. Neural Plast 2012, 247150.
44. Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, Plotkine M, Marchand-Verrecchia C,Vivien D, Buisson A(2005)NMDAreceptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 25, 9367-9377.
45. Tovar KR, Westbrook GL (1999) The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19, 4180-4188.
46. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD (2009) Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience 158, 1446-1459.
47. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235.
48. Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, Hajj GN, Lee KS, Magalhaes AC, Caetano FA, Mancini GL, Lopes MH, Americo TA, Magdesian MH, Ferguson SS, Linden R, Prado MA,Martins VR (2011) Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma1 chain. FASEB J 25, 265-279.
49. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5, 405-414.
50. Zhou Q, Sheng M (2013) NMDA receptors in nervous system diseases. Neuropharmacology 74, 69-75.
51. Baudry M, Lynch G (2001) Remembrance of arguments past: How well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiol Learn Mem 76, 284-297.
52. Escobar ML, Derrick B (2007) Long-term potentiation and depression as putative mechanisms for memory formation. In Neural Plasticity and Memory: From Genes to Brain Imaging, Bermudez-Rattoni F, ed. CRC Press, Boca Raton (FL), pp. 15-45.
53. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140.
54. Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ (2001) Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 21, 1327-1333.
55. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depress d dendritic spine loss. Neuron 52, 831-843.
56. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, NairnAC, SalterMW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
57. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14, 69-76.
58. Collingridge GL, Isaac JT, Wang YT (2004) Receptor trafficking and synaptic plasticity. Nat Rev Neurosci 5, 952-962.
59. Kessels HW, Nabavi S, Malinow R (2013) Metabotropic NMDA receptor function is required for beta-amyloidinduced synaptic depression. Proc Natl Acad Sci USA 110, 4033-4038.
60. Nosyreva E, Szabla K, Autry AE, RyazanovAG, Monteggia LM, Kavalali ET (2013) Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 33, 6990-7002.
61. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, III, Kandel ER, DuffK, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36.
62. Corlew R, Wang Y, Ghermazien H, Erisir A, Philpot BD (2007) Developmental switch in the contribution of presynaptic and postsynaptic NMDA receptors to long-term depression. J Neurosci 27, 9835-9845.
63. Aoki C, Lee J, Nedelescu H, Ahmed T, Ho A, Shen J (2009) Increased levels of NMDA receptor NR2A subunits at preand postsynaptic sites of the hippocampal CA1: An early response to conditional double knockout of presenilin 1 and 2. J Comp Neurol 517, 512-523.
64. Gastard MC, Troncoso JC, Koliatsos VE (2003) Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 54, 393-398.
65. Parameshwaran K, Dhanasekaran M, Suppiramaniam V (2008) Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 210, 7-13.
66. Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC (2012) Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51, 95-106.
67. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, Tymianski M (1999) Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845-1848.
68. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27, 2846-2857.
69. Bordji K, Becerril-Ortega J, Nicole O, Buisson A (2010) Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. J Neurosci 30, 15927-15942.
70. Danysz W, Parsons CG (2012) Alzheimer's disease, beta-amyloid, glutamate,NMDAreceptors and memantine-searching for the connections. Br J Pharmacol 167, 324-352.
71. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA 103, 2892-2897.
72. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081.
73. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J,Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387-397.
74. Matos M, Augusto E, Oliveira CR, Agostinho P (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156, 898-910.
75. Novelli A, Reilly JA, Lysko PG, HenneberryRC(1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451, 205-212.
76. Huang YJ, Lin CH, Lane HY, Tsai GE (2012) NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease. Curr Neuropharmacol 10, 272-285.
77. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26, 503-513.
78. Muir KW (2006) Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists. Curr Opin Pharmacol 6, 53-60.
79. Lipton SA (2004) Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis 6, S61-S74.
80. Xia P, Chen HS, Zhang D, Lipton SA (2010) Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 30, 11246-11250.
81. Grimwood S, Gilbert E, Ragan CI, Hutson PH (1996) Modulation of 45Ca2+influx into cells stably expressing recombinant human NMDA receptors by ligands acting at distinct recognition sites. J Neurochem 66, 2589-2595.
82. Ray B, Banerjee PK, Greig NH, Lahiri DK (2010) Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett 470, 1-5.
83. Wilkinson D (2012) A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 27, 769-776.
84. Yang Z, Zhou X, ZhangQ(2013) Effectiveness and safety of memantine treatment for Alzheimer's disease. J Alzheimers Dis 36, 445-458.
85. Parsons CG, Stoffler A, Danysz W (2007) Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53, 699-723.
86. Zadori D, Klivenyi P, Plangar I, Toldi J, Vecsei L (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: With particular regard to the kynurenines. J Cell Mol Med 15, 701-717.
87. Zadori D, Klivenyi P, Szalardy L, Fulop F, Toldi J, Vecsei L (2012) Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders. J Neurol Sci 322, 187-191.
88. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 13, 465-477.
89. Vecsei L, Szalardy L, Fulop F, Toldi J (2013) Kynurenines in the CNS: Recent advances and new questions. Nat Rev Drug Discov 12, 64-82.
90. Plangar I, Zadori D, Klivenyi P, Toldi J, Vecsei L (2011) Targeting the kynurenine pathway-related alterations in Alzheimer's disease: A future therapeutic strategy. J Alzheimers Dis 24(Suppl 2), 199-209.
91. Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247, 184-187.
92. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J Neurochem 52, 1319-1328.
93. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45, 309-379.
94. Swartz KJ, During MJ, Freese A, Beal MF (1990) Cerebral synthesis and release of kynurenic acid: An endogenous antagonist of excitatory amino acid receptors. J Neurosci 10, 2965-2973.
95. Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S (2010) Role of the NMDA-receptor in prepulse inhibition in the rat. Int J Tryptophan Res 3, 1-12.
96. Vecsei L, BealMF(1991) Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196, 239-246.
97. Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106, 165-181.
98. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35, 1734-1742.
99. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implications. J Neurosci 21, 7463-7473.
100. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M (2002) Direct evidence that release-stimulating alpha7∗ nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80, 1071-1078.
101. Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R (2011) Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36, 2357-2367.
102. Prescott C, Weeks AM, Staley KJ, Partin KM (2006) Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402, 108-112.
103. Rozsa E, Robotka H,Vecsei L, Toldi J (2008) The Janus-face kynurenic acid. J Neural Transm 115, 1087-1091.
104. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. Br J Pharmacol 157, 1301-1317.
105. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44, 851-859.
106. Kew JN, Kemp JA (1998) An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512(Pt 1), 17-28.
107. Han X, Tomitori H, Mizuno S, Higashi K, Full C, Fukiwake T, Terui Y, Leewanich P, Nishimura K, Toida T, Williams K, Kashiwagi K, Igarashi K (2008) Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor. J Neurochem 107, 1566-1577.
108. Costa RO, Lacor PN, Ferreira IL, Resende R, Auberson YP, Klein WL, Oliveira CR, RegoAC, PereiraCM(2012) Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures treated with amyloid-beta oligomers. Aging Cell 11, 823-833.
109. Hu NW, Klyubin I, Anwyl R, Rowan MJ (2009) GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci USA 106, 20504-20509.
110. Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG (2011) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 32, 2219-2228.
111. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containingNMDA receptors. J Neurosci 31, 6627-6638.
112. Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2Bcontaining NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990.
113. Wong TP, Howland JG, Robillard JM, Ge Y, Yu W, Titterness AK, Brebner K, Liu L, Weinberg J, Christie BR, Phillips AG, Wang YT (2007) Hippocampal long-term depression mediates acute stress-induced spatial memory retrieval impairment. Proc Natl Acad Sci USA 104, 11471-11476.
114. Fulop F, Szatmari I, Vamos E, Zadori D, Toldi J, Vecsei L (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16, 4828-4842.
115. Nagy K, Plangar I, Tuka B, Gellert L, Varga D, Demeter I, Farkas T, Kis Z, Marosi M, Zadori D, Klivenyi P, Fulop F, Szatmari I,Vecsei L, Toldi J (2011) Synthesis and biological effects of some kynurenic acid analogs. Bioorg Med Chem 19, 7590-7596.
116. Borza I, Kolok S, Galgoczy K, Gere A, Horvath C, Farkas S, Greiner I, Domany G (2007) Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 17, 406-409.
117. Gellert L, Fuzik J, Goblos A, Sarkozi K, Marosi M, Kis Z, Farkas T, Szatmari I, Fulop F, Vecsei L, Toldi J (2011) Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 667, 182-187.
118. Zadori D, Nyiri G, Szonyi A, Szatmari I, Fulop F, Toldi J, Freund TF, Vecsei L, Klivenyi P (2011) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm 118, 865-875.
119. Caraci F, Battaglia G, Sortino MA, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V (2012) Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic? Neurochem Int 61, 559-565.
120. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. Front Biosci 13, 2614-2632.
121. Rahman A (2009) The role of adenosine in Alzheimer's disease. Curr Neuropharmacol 7, 207-216.
122. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
123. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155-1162.